These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1827847)

  • 61. Prevention of postmenopausal bone loss and endometrial responses during a two year prospective study with transdermal 17 beta-estradiol and oral medroxyprogesterone acetate.
    Fioretti P; Gambacciani M; Spinetti A; Cagnacci A; Paoletti AM; Felipetto R; Melis GB
    Ann N Y Acad Sci; 1991; 622():302-6. PubMed ID: 1829595
    [No Abstract]   [Full Text] [Related]  

  • 62. High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.
    Kjaer M; Frederiksen PL
    Cancer Treat Rep; 1986 Mar; 70(3):431-2. PubMed ID: 2937534
    [No Abstract]   [Full Text] [Related]  

  • 63. Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation.
    Kager M; Spruss T; Schneider MR; von Angerer E
    J Cancer Res Clin Oncol; 1992; 118(5):334-8. PubMed ID: 1583064
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hormonal therapy of advanced prostatic cancer.
    Fair WR
    J Urol; 1986 Sep; 136(3):653-4. PubMed ID: 2942708
    [No Abstract]   [Full Text] [Related]  

  • 65. Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer.
    Sasagawa I; Satomi S
    Br J Urol; 1990 Mar; 65(3):278-81. PubMed ID: 1692498
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82).
    van Steenbrugge GJ; Groen M; Romijn JC; Schröder FH
    J Urol; 1984 Apr; 131(4):812-7. PubMed ID: 6708205
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R
    J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.
    Hamerlynck JV; Maskens AP; Mangioni C; van der Burg ME; Wils JA; Vermorken JB; Rotmensz N
    Gynecol Oncol; 1985 Nov; 22(3):313-6. PubMed ID: 2998957
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
    Dowsett M; Lal A; Smith IE; Jeffcoate SL
    Br J Cancer; 1987 Mar; 55(3):311-3. PubMed ID: 2952154
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lack of gonadal protection by medroxyprogesterone acetate-induced transient medical castration during chemotherapy for testicular cancer.
    Fosså SD; Klepp O; Norman N
    Br J Urol; 1988 Nov; 62(5):449-53. PubMed ID: 2850071
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of zindoxifene on experimental prostatic tumours of the rat.
    Schneider MR; Schiller CD; Humm A; von Angerer E
    J Cancer Res Clin Oncol; 1991; 117(1):33-6. PubMed ID: 1997466
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of oestrogen on growth and morphology of the Dunning R3327H prostatic carcinoma.
    Damber JE; Daehlin L; Bergh A; Landström M; Tomic R
    Prog Clin Biol Res; 1987; 243A():513-6. PubMed ID: 3659008
    [No Abstract]   [Full Text] [Related]  

  • 74. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
    Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R
    Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
    [No Abstract]   [Full Text] [Related]  

  • 75. Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer.
    Anderström C
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S97-100. PubMed ID: 7994797
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
    Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines.
    Sica G; Iacopino F; Marini L; Robustelli della Cuna G
    Clin Ther; 1992; 14 Suppl A():87-96. PubMed ID: 1535023
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
    English HF; Heitjan DF; Lancaster S; Santen RJ
    Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer.
    Rao BR; Geldof AA; van der Wilt CL; de Voogt HJ
    Prostate; 1988; 13(1):69-78. PubMed ID: 3420036
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762.
    deVoogt HJ; Pavone-Macaluso M; Sylvester R; Schröder FH
    J Urol; 1988 Dec; 140(6):1557. PubMed ID: 2973530
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.